The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer
Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, discusses the results of the FIGHT study (NCT03694522), a double-blind placebo-controlled Phase II study of bemarituzumab, an FGFR2b targeting antibody in combination with modified FOLFOX6 (mFOLFOX6) in the first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
